In summary, positivity for either ERβ, Her2, or both proteins was observed in 91% (142/156) of CIS cases, while normal urothelium showed significantly lower expression of both markers, highlighting their potential for clinical use. The gene discussed is ERBB2; the disease is in situ carcinoma.